This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Intercept Pharmaceuticals, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovations of Tadashi Namisaki
Introduction
Tadashi Namisaki is a notable inventor based in Nara, Japan. He has made significant contributions to the field of medicine, particularly in the development of therapeutic agents for non-alcoholic steatohepatitis (NASH). His innovative approach combines different pharmacological agents to enhance treatment efficacy.
Latest Patents
Tadashi Namisaki holds a patent for a medicine obtained by combining an FXR agonist and an angiotensin receptor blocker (ARB). The present invention provides an NASH therapeutic agent that includes an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof, along with an ARB or a pharmaceutically acceptable salt thereof. This patent represents a significant advancement in the treatment of liver diseases.
Career Highlights
Tadashi Namisaki is currently associated with Intercept Pharmaceuticals, Inc., where he continues to work on innovative solutions for liver-related health issues. His expertise and dedication to research have positioned him as a key figure in the pharmaceutical industry.
Collaborations
Tadashi Namisaki collaborates with Hitoshi Yoshiji, contributing to the advancement of medical research and the development of new therapeutic strategies.
Conclusion
Tadashi Namisaki's work exemplifies the spirit of innovation in the medical field. His contributions, particularly in the area of NASH treatment, highlight the importance of combining different therapeutic agents to improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile